Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S. Steelman, James A. McCubrey|Aging|2011Cited by 699
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human HealthWilliam H. Chappell, James A. McCubrey|Oncotarget|2011Cited by 575
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemiaLinda S. Steelman, James A. McCubrey|Leukemia|2008Cited by 396
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome ResistanceJames A. McCubrey, Alberto M. Martelli|Oncotarget|2012Cited by 315
Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.James A. McCubrey, Alberto M. Martelli|Oncotarget|2012Cited by 303